Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Broodman, Ingrid; VanDuijn, Martijn M.; Stingl, Christoph; Dekker, Lennard J. M.; Germenis, Anastasios E.; Koning, Harry J. de; Klaveren, Rob J. van; Aerts, Joachim; Lindemans, Jan; Luider, Theo M.

doi:10.1158/2326-6066.cir-14-0176

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent report by the National Cancer Center, China, indicated that lung cancer was also the first cause of cancer death in China; in 2013, about 733 000 cases were newly diagnosed with lung cancer and about 591 000 cases that died of lung cancer [4]. Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of all cases with this malignancy [5].The high mortality rate of lung cancer is largely attributable to late diagnosis [6]. If this malignant tumor was identified at stage 1, the 5-year survival rate can rise from less than 15% on average to 50% [7].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

et al. 2018

View full text Add to dashboard Cite

A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat‐containing protein 5 isoform 2 ( BIRC 5) and myc proto‐oncogene protein ( MYC ) were significantly increased in nonsmall cell lung cancer ( NSCLC ). This study was undertaken to replicate this initial work in an independent sample. An enzyme‐linked immunosorbent assay ( ELISA ) was developed in‐house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC 5a, BIRC 5b, and MYC in 211 patients with NSCLC and 200 control subjects. A Mann–Whitney U ‐test demonstrated that plasma anti‐ BIRC 5a IgG levels, but not anti‐ BIRC 5b or anti‐ MYC IgG levels, were significantly higher in NSCLC patients than control subjects, especially in male patients. Both squamous cell cancer and adenocarcinoma showed increased anti‐ BIRC 5a IgG levels, but the IgG levels were not found to be changed significantly in the early stage of NSCLC . Kaplan–Meier survival analysis showed that NSCLC patients with high anti‐ BIRC 5b IgG levels had better prognosis and longer overall survival ( OS ) than patients with low anti‐ BIRC 5b IgG levels, although this significant difference failed to survive the adjustment for age, gender, NSCLC stages, and types. Plasma anti‐ BIRC 5a and MYC IgG levels did not show significant associations with OS . In conclusion, Plasma anti‐ BIRC 5 IgG may be a useful marker for assessment of prognosis of NSCLC but not for early diagnosis of this malignancy.

show abstract

mentioning

confidence: 99%

“…The high mortality rate of lung cancer is largely attributable to late diagnosis [6]. If this malignant tumor was identified at stage 1, the 5-year survival rate can rise from less than 15% on average to 50% [7].…”

mentioning

confidence: 99%

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The autoantibody repertoire of patients who were administrated treatment has been shown to differ from the autoantibody repertoire of newly diagnosed patients (17); hence, it seemed good if the data on the treatments administrated for these patients (treatment history) were added. Smoking, as the major risk factor for lung cancer, has been considered in different studies (3,9,18). However, this study lacked any data regarding whether the patients and healthy individuals (as controls) were smokers or non-smokers.…”

Section: Editorialmentioning

confidence: 99%

“…Four TAAs, including cyclin B1, HCC1, p53, and survivin, were used in this study to evaluate their potential as cancer biomarkers. As the authors pointed out, the roles of these TAAs in lung cancer have been demonstrated in many studies (9,10,(16)(17)(18)(20)(21)(22)(23)(24)(25)(26). Because the diagnostic value of a single marker is relatively low, different combinations of these antigens were also used to simultaneously detect antibodies associated with lung cancer (9,10,20,21,26).…”

Section: Editorialmentioning

confidence: 99%

The state of the art in the development of a panel of biomarkers for the early detection of lung cancer

Jamnani

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

“…Other types include lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma ( 5 ). Due to the nonspecific symptoms at early stages and poor overall survival rates ( 6 , 7 ), association studies for NSCLC biomarkers have been investigated globally ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Hypermethylation of MDFI promoter with NSCLC is specific for females, non‑smokers and people younger than 65

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Non-small cell lung carcinoma (NSCLC) is a major subtype of lung cancer. Aberrant DNA methylation has been frequently observed in NSCLC. The aim of the present study was to investigate the role of MyoD family inhibitor (MDFI) methylation in NSCLC. Formalin-fixed paraffin-embedded tumor tissues and adjacent non-cancerous tissues were collected from a total of 111 patients with NSCLC. A methylation assay was performed using the quantitative methylation-specific polymerase chain reaction method. The percentage of methylated reference was used to represent the methylation level of the MDFI promoter. Data mining of a dataset from The Cancer Genome Atlas (TCGA) demonstrated that MDFI promoter methylation levels were significantly increased in 830 tumor tissues compared with 75 non-tumor tissues (P=0.012). However, the results on tissues obtained in the present study indicated that the MDFI promoter methylation levels in tumor tissues were not significantly different compared with those in the adjacent non-tumor tissues (P=0.159). Subsequent breakdown analysis identified that higher MDFI promoter methylation levels were significantly associated with NSCLC in females (P=0.031), but not in males (P=0.832). Age-based subgroup analysis demonstrated that higher MDFI promoter methylation levels were significantly associated with NSCLC in younger patients (≤65 years; P=0.003), but not in older patients (P=0.327). In addition, the association of MDFI methylation with NSCLC was significant in non-smokers (P=0.014), but not in smokers (P=0.832). Similar results also have been determined from subgroup analysis of the TCGA datasets. The Gene Expression Omnibus database indicated MDFI expression restoration in partial lung cancer cell lines (H1299 and Hotz) following demethylation treatment. However, it was identified that MDFI promoter hypermethylation was not significantly associated with prognosis of NSCLC (P>0.05). In conclusion, the present study indicated that the association of higher methylation of the MDFI promoter with NSCLC may be specific to females, non-smokers and people aged ≤65.

show abstract

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Cited by 5 publications

References 25 publications

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

The state of the art in the development of a panel of biomarkers for the early detection of lung cancer

Hypermethylation of MDFI promoter with NSCLC is specific for females, non‑smokers and people younger than 65

Contact Info

Product

Resources

About